- General Meeting (PL)
- Corporate documents
- Shares and Shareholders
- IPO (PL)
Progress in research and development related to CT-3 project and disclosure of molecular target in CT-3 project
Number: RB ESPI 27/2021
Current Report No. 27/2021
Date of preparation: 28 September 2021
Subject: Progress in research and development related to CT-3 project and disclosure of molecular target in CT-3 project
Legal basis: Art. 17(1) of MAR – inside information
The Management Board of Captor Therapeutics S.A. with its registered office in Wrocław ("Company") hereby informs about progress in research and development related to the CT-3 project (induction of apoptosis using small-molecule chemical compounds as a therapeutic intervention in cancer disorders) and discloses molecular target in CT-3 project.
The Company obtained and verified scientific results which indicate that the compounds developed by the Company potently degrade “Induced Myeloid Leukaemia Cell Differentiation Protein” (commonly called MCL-1 which is the molecular target of the CT-3 project) across a wide range of cancer cell lines.
The above results obtained by the Company demonstrate the following properties of the CT-3 compounds :
- CT-3 compounds induce programmed cell death, apoptosis, in vitro in different haematological cancer and solid tumour cell lines
- pharmacodynamic effect, i.e. in vivo degradation of MCL-1 in tumour-bearing mice in a leukaemia model (MV4-11)
- strong induction of apoptosis in vivo in an MV4-11 leukaemia model, as a consequence of degradation of MCL-1
The molecular target of CT-3 project, i.e. MCL-1, belongs to the Bcl-2 family of proteins. The Bcl-2 family consists of both pro- and antiapoptotic proteins that dictate cell fate via series of competitive protein-protein interactions. MCL-1 serves as a major pro-survival signal in many cancers and functions as a resistance mechanism to BCL2 inhibition, thus degrading the MCL-1 target is an attractive approach for treating several different tumour types. Despite significant effort, no MCL-1 targeting drug has been approved so far.
The Company will present preclinical data mentioned above which show the characterization of novel, highly potent degraders of MCL-1 at the Targeted Protein Degradation Summit on 28th October 2021 at 12:00 EDT (16:00 CEST).
The Company will inform about further progress in CT-3 project in accordance with legal requirements.